Compare AstraZeneca plc (AZN) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs JPMorgan Chase & Co — how do they compare? AstraZeneca plc trades at $156 (market cap $245.16B), while JPMorgan Chase & Co trades at $363.1 (market cap $970.72B). The key difference: JPMorgan Chase & Co is far larger — about 4× AstraZeneca plc's market cap, and AstraZeneca plc pays the higher dividend (2.02%). Which is the better fit depends on your goals.
| AZN | JPM | |
|---|---|---|
Market Cap | $245.16B | $970.72B |
Sector | Health | Financials |
52-Week High | $209.48 | $365.18 |
52-Week Low | $147.06 | $282.84 |
Enterprise Value | $272.43B | — |
Dividend Yield | 2.02% | 1.64% |
Volume | — | 10,479,943 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.24, down 0.95% on the day, amid bearish technical signals and merger speculation. The company shows strong fundamentals with revenue growth from $44.4B in 2022 to $58.7B in 2025 and net income margin improving to 17.4%. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing selling pressure and legal investigations creating near-term uncertainty.
AZN presents a mixed outlook with strong pharmaceutical fundamentals offset by technical weakness and merger-related volatility. The investment case hinges on continued earnings growth and strategic execution, while risks include integration challenges from potential M&A and ongoing legal scrutiny. Wall Street remains predominantly bullish despite recent price pressure.
JPMorgan Chase (JPM) trades at $365.18, up 0.87% with strong technical momentum and bullish moving averages. The company reported solid Q1 2026 earnings beat ($5.94 vs. $5.47 expected) and maintains robust profitability with 33.38% net income margin and 18.43% ROE. Analyst consensus is moderately bullish with 51.67% buy ratings and $374.18 price target. Recent news highlights CEO Jamie Dimon's economic warnings and upcoming Q1 earnings catalyst.
JPMorgan presents a compelling investment case with strong fundamentals and positive earnings momentum, though risks include geopolitical tensions impacting banking operations and elevated RSI levels suggesting potential near-term consolidation. The stock's valuation at 15.65 P/E remains reasonable relative to historical levels, supporting upside potential toward analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
